CVS Health (NYSE:CVS) Updates FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 5.750-6.000 for the period, compared to the consensus estimate of 5.970. The company issued revenue guidance of -.

CVS Health Price Performance

Shares of NYSE CVS traded up $8.71 during midday trading on Wednesday, reaching $63.71. The stock had a trading volume of 11,981,160 shares, compared to its average volume of 12,304,292. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. CVS Health has a 12-month low of $43.56 and a 12-month high of $80.75. The stock has a 50-day moving average of $50.61 and a 200-day moving average of $55.92. The company has a market capitalization of $80.18 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 0.60 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. As a group, research analysts anticipate that CVS Health will post 5.14 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.17%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s payout ratio is currently 67.51%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CVS. Evercore ISI raised their target price on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Monday, January 27th. Piper Sandler cut their price objective on CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research report on Tuesday, December 3rd. Mizuho reduced their price objective on CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, StockNews.com downgraded CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average target price of $67.78.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.